比较鲁拉西酮与奥氮平治疗精神分裂症的临床效果及对患者认知功能的影响

doi:10.3969/j.issn.1671-7171.2025.03.020

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1196 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To compare the clinical efficacy and their impact on patients' cognitive function of lurasidone and olanzapine in the treatment of schizophrenia.【Methods】A total of 116 patients with schizophrenia admitted to Baoshan District Mental Health Center in Shanghai from August 2020 to December 2023 were selected and randomly divided into two groups using a random number table: the lurasidone group and the olanzapine group, with 58 patients in each group. Both groups of patients were treated for 12 weeks, and their clinical symptom improvement, cognitive function, biochemical indicators of neurological function [nerve growth factor (NGF), gamma aminobutyric acid (GABA), specific enolase (NSE)], inflammatory and metabolic indicators [interleukin-4 (IL-4), interleukin-8 (IL-8), triglycerides (TG), body mass index (BMI)], and incidence of adverse reactions were compared. 【Results】The scores of the Negative and Positive Symptom Scale (PANSS) in both groups were lower than those before treatment, and the PANSS scores in the lurasidone group were lower than those in the olanzapine group, with statistically significant differences (P<0.05). At the 4th and 12th week of treatment, the MCCB scores of both groups were higher than those before treatment, and the MCCB score of the lurasidone group was higher than that of the olanzapine group, with statistical significance (P<0.05). After treatment, the levels of serum NGF and GABA in both groups were higher than those before treatment, and the levels of serum NGF and GABA in the lurasidone group were higher than those in the olanzapine group, with statistical significance (P<0.05). The serum NSE levels in both groups were lower than those before treatment, and the level in the lurasidone group was lower than that in the olanzapine group, with statistically significant difference (P<0.05). After treatment, the average levels of IL-4 and IL-8 in the serum of both groups were lower than those before treatment. The levels of IL-4 and IL-8 in the lurasidone group were lower than those in the olanzapine group. The BMI and TG in the lurasidone group were lower than before treatment and both BMI and TG were lower than those in the olanzapine group, with statistical significance (P<0.05); After treatment, there was no statistically significant difference in BMI and TG in the olanzapine group if compared to before treatment (P>0.05). The total incidence of adverse reactions in the lurasidone group was 8.62% (5/58), which was lower than the 24.14% (14/58) in the olanzapine group, and the difference was statistically significant (P=0.024). 【Conclusion】Lurasidone can improve cognitive function, reduce levels of inflammatory factors, and not increase the risk of metabolic disorders in patients with schizophrenia. It has a low incidence of adverse reactions and good safety.

Key words： Schizophrenia Lurasidone Hydrochlorid Olanzapine Cognition Treatment Outcome

Received: 04 December 2024

PACS:

R749.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Gongquan
	CAO Linjia
	XIE Qingfang

Cite this article:

LI Gongquan,CAO Linjia,XIE Qingfang. Comparison of the Clinical Efficacy and Impact on Cognitive Function of Lorazepine and Olanzapine in the Treatment of Schizophrenia[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 437-440.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.03.020 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I3/437

[1] 杨凡,徐沛琳,黄悦勤,等.不同首发年龄精神分裂症患者临床特征及影响因素[J].中国心理卫生杂志,2024,38(1):16-24.
[2] 陈杰,宋立平,曾宽,等.鲁拉西酮与利培酮治疗急性期精神分裂症患者的临床研究[J].中国临床药理学杂志,2024,40(16):2307-2310.
[3] 司天梅,赵靖平,于欣,等.鲁拉西酮治疗精神分裂症临床应用专家建议[J].中国心理卫生杂志,2022,36(6):457-464.
[4] 黄焱,王能焜,谢清芳.鲁拉西酮联合认知行为干预对精神分裂症患者执行及记忆功能的影响[J].医学临床研究,2023,40(5):790-792.
[5] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,200l,34(3):184-188.
[6] 杜恬恬,梁学军,史振娟,等. 改良电休克联合高频rTMS在精神分裂症患者中的应用效果及对患者认知功能的影响[J].医学临床研究,2024,41(4):496-499.
[7] 严佳.精神分裂症患者主观睡眠质量及与PANSS评分和认知功能的相关性研究[J].河北医药,2021,43(18):2814-2817.
[8] 郭年春,王婧,于欣.事件相关电位对精神分裂症高危人群早期识别及转化研究(综述)[J].中国心理卫生杂志,2024,38(3):200-205.
[9] 杜兴梅,杨中婷,邓睿,等.5种给药方案治疗精神分裂症的成本效果分析[J].中国新药杂志,2024,33(19):2067-2074.
[10] 彭四新,孙秋芳,李鸿,等.布南色林联合鲁拉西酮在精神分裂症治疗中的应用价值及其对糖脂代谢的影响[J].吉林医学,2024,45(5):1136-1139.
[11] 陈旭,梁世桥,冯嫒,等.鲁拉西酮与利培酮对中国精神分裂症患者催乳素水平影响的比较[J].中国新药与临床杂志,2021,40(12):839-843.
[12] 陈玉清,杨烨,戴丽静,等.新型抗精神障碍药鲁拉西酮个体化用药研究进展[J].广东药科大学学报,2023,39(5):126-134.
[13] 杨华. 奥氮平片所致78例药物不良反应的临床分析[J].现代诊断与治疗,2022,33(8):1148-1150.
[14] 郑昊,黄敏,褚强强.阿立哌唑联合奥氮平对体重超重精神分裂症患者糖脂代谢及成纤维细胞生长因子21的影响[J].国际精神病学杂志,2021,48(2):224-228.